On this page
Back to topPolaryx Therapeutics PLYX
Polaryx Therapeutics listed on Nasdaq on 2 Feb 2026 and is not in the S&P 500. It is worth $75.3 million. Its price history starts on 13 Feb 2026. Its board has 5 directors, 3 of them independent. 1 other officer is on file.
- Chair and CEO
- Alex Keun Mo Yang
- Listed
- 2 Feb 2026 on Nasdaq, IPO filings and terms
- Headquarters
- Paramus, NJ
- Market cap
- $75M
- 19 Nov 2026 close
- Revenue
- -
- No annual report yet
Financials
Polaryx Therapeutics' market cap since February 2026
Weekly, up to 13 Nov 2026
| Week ending | Market cap |
|---|---|
| 13 Nov 2026 | $90M |
Download Polaryx Therapeutics' data as JSON, with the weekly market caps in billions of dollars from 13 Feb 2026.
Board and leadership
Board and officers
Board from the proxy filed 28 Jul 2026; officers filed up to 30 Sep 2026
| Name | Title | Since | Independent | Committees | Age |
|---|---|---|---|---|---|
| Directors (5) | |||||
| Alex Keun Mo YangChair; Chief Executive OfficerNot independent 路 since 2021 | |||||
| Mitchel BergerDirectorIndependent 路 since 2026 路 Audit, Compensation (chair), GovernanceDirector of the Brain Tumor Center, University of California, San Francisco | |||||
| Francis A. Braun IIIDirectorIndependent 路 since 2026 路 Audit (chair)Senior Advisor, Stout Risius Ross, LLCOther boards: SHF Holdings | |||||
| G. Michael LandisChief Financial OfficerNot independent 路 since 2025 | |||||
| Charles S. RyanLead Independent DirectorIndependent 路 since 2026 路 Audit, Compensation, Governance (chair)President, Quince Therapeutics, Inc.Other boards: Quince Therapeutics | |||||
| Officers (1) | |||||
| O. Andrew JohnChief Investment OfficerLast filed 29 Jan 2026 | |||||
Owners and trading
Insider trades
Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.
Trades from 19 Nov 2025 to 19 Nov 2026
Directors and officers made no open-market sales and bought $368,003 in 2 purchases in the 12 months to 19 Nov 2026.
| Date | Person | Value |
|---|---|---|
| 27 May 2026Buy | Alex Keun Mo YangChief Executive Officer | $360K |
| 18 Feb 2026Buy | G. Michael LandisChief Financial Officer | $8K |
Timeline
Leadership changes, layoffs and insider sales
20 Nov 2024 to 20 Nov 2026; insider sales from 19 Nov 2025
1 departure and 0 appointments of directors and officers in the last two years.
Events, newest first
- 19 Jul 2026 Lisa Bollinger resignedChief Medical Officer
| Date | Event | Filing |
|---|---|---|
| 19 Jul 2026 | Lisa Bollinger resignedChief Medical Officer | 8-K |
Not on file: no 13F holdings reported, no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months and no quarterly results in its SEC XBRL filings.